Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Not Yet Opened 11-10 16:00:00 EST

136.64

-2.22

-1.60%

盘后140.00

+3.36+2.46%

19:59 EST

High142.92	Low136.01	Vol995.59K
Open138.86	D1 Closing138.86	Amplitude4.98%
Mkt Cap11.67B	Tradable Cap9.33B	Total Shares85.37M
T/O137.17M	T/O Rate1.46%	Tradable Shares68.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":136.64,"timestamp":1794344400000,"preClose":138.86,"halted":0,"volume":995591,"hourTrading":{"tag":"盘后","latestPrice":140,"preClose":136.64,"latestTime":"19:59 EST","volume":10650,"amount":1456659.1685,"timestamp":1794358791256,"change":3.36,"changeRate":0.02459,"amplitude":0.02459},"delay":0,"changeRate":-0.01598732536367584,"floatShares":68261000,"shares":85371400,"eps":-3.622488,"marketStatus":"Not Yet Opened","change":-2.22,"latestTime":"11-10 16:00:00 EST","open":138.86,"high":142.92,"low":136.01,"amount":137165041.13568,"amplitude":0.049762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.622488,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794387600000},"marketStatusCode":0,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":138.86,"preHourTrading":{"tag":"盘前","latestPrice":136,"preClose":138.86,"latestTime":"09:24 EST","volume":445,"amount":61657.78489999999,"timestamp":1794320655976,"change":-2.86,"changeRate":-0.020596,"amplitude":0.039608},"postHourTrading":{"tag":"盘后","latestPrice":140,"preClose":136.64,"latestTime":"19:59 EST","volume":10650,"amount":1456659.1685,"timestamp":1794358791256,"change":3.36,"changeRate":0.02459,"amplitude":0.02459},"volumeRatio":0.710131,"impliedVol":2.1471,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/KYMR/","defaultTab":"news","newsList":[{"id":"2681111811","title":"Kymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2681111811","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681111811?lang=en_us&edition=fundamental","pubTime":"2026-11-07 15:34","pubTimestamp":1794036875,"startTime":"0","endTime":"0","summary":"BBailey PembertonNovember 7, 2026","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680983557","title":"Kymera Therapeutics is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2680983557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680983557?lang=en_us&edition=fundamental","pubTime":"2026-11-03 04:56","pubTimestamp":1793652960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680752523","title":"S&P 500 Futures Climb in Premarket Trading; Moog, Kymera Therapeutics Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2680752523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680752523?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:30","pubTimestamp":1793622600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Moog Inc. Cl A (MOG.A) was up 17.7% in pre-market tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOOX","UXJA","DSPY","CFO","FEBT","HJUN","KYMR","UOCT","VUG","XSPI","ACLC","UXAP","UXJL","BKLC","VSL","LGDX","SPY","VOO","VYM","SPDF","LGH","PTLC","XPAY","MRCP","CGUS","GPIX","TSPA","TSEM","HELO","PBJL","OALC","CPST","POR","GBXB","VOOG","XUSP","XXX","GSUS","ISSXF","FLAO",".SPX","FELC","DBB","SCHG","SSS","TOPC","PTL","FLCC","ABIG","SPYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680753747","title":"Kymera Therapeutics price target raised to $170 from $139 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2680753747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680753747?lang=en_us&edition=fundamental","pubTime":"2026-11-02 18:35","pubTimestamp":1793615727,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $170 from $139 and keeps an Overweight rating on the shares. The company r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-170-from-139-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-170-from-139-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680789175","title":"Kymera Therapeutics (KYMR) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2680789175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680789175?lang=en_us&edition=fundamental","pubTime":"2026-11-02 09:35","pubTimestamp":1793583342,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee maintained a Buy rating on Kymera Therapeutics yesterday and set a price target of $139.00. According to TipRanks, Mukh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kymera-therapeutics-kymr-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kymera-therapeutics-kymr-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680678606","title":"Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Thermo Fisher (TMO) and AbbVie (ABBV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680678606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680678606?lang=en_us&edition=fundamental","pubTime":"2026-11-02 09:20","pubTimestamp":1793582431,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kymera Therapeutics (KYMR), Thermo Fisher (TMO) and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-thermo-fisher-tmo-and-abbvie-abbv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-thermo-fisher-tmo-and-abbvie-abbv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0198837287.USD","FTXH","VHT","PJP","XBI","FHLC","LABU","LU1712237335.SGD","RXL","IE00BQXX3F31.USD","FMED","LU2237443382.USD","LU1623119135.USD","LU1633808545.USD","GNMX","LU2089284900.SGD","SG9999015986.USD","IE00B19Z3B42.SGD","HCSG","LU0310800379.SGD","AGNG","GLAM","ABBV","KYMR","JDOC","TRUH","LU2041044095.USD","IE0004445239.USD","LU0029864427.USD","LU0795875086.SGD","LU2125909593.SGD","IE00B1BXHZ80.USD","TMO","TMED","LU1803068623.USD","MEDX","HRTS","LU0689626769.HKD","IYH","IXJ","LU0965509283.SGD","LU1854104046.USD","LU0057025933.USD","IE000F7OJYX1.SGD","SG9999001440.SGD","LU0345770308.USD","XLV","PPH","IE00BLSP4239.USD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680773762","title":"Kymera Therapeutics Earnings Call Highlights Biotech Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2680773762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680773762?lang=en_us&edition=fundamental","pubTime":"2026-11-01 08:07","pubTimestamp":1793491637,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. (($KYMR)) has held its Q3 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ latest earning...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-biotech-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-biotech-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679249890","title":"KT-621 Formulation Study: What Kymera’s New Phase 1 Update Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2679249890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679249890?lang=en_us&edition=fundamental","pubTime":"2026-10-31 00:31","pubTimestamp":1793377868,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. ($KYMR) announced an update on their ongoing clinical study. Kymera Therapeutics, Inc. is running a Phase 1 study called ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kt-621-formulation-study-what-kymeras-new-phase-1-update-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kt-621-formulation-study-what-kymeras-new-phase-1-update-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4115","BK4211","KT","ISBC","LU0541502299.USD","KYMR","LU0541501648.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679453246","title":"Kymera Therapeutics Remains Optimistic on KT-621's Phase 2 Data in Atopic Dermatitis, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2679453246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679453246?lang=en_us&edition=fundamental","pubTime":"2026-10-31 00:15","pubTimestamp":1793376959,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics  remains optimistic over the phase 2 trial topline data on KT-621 in atopic dermatitis, which is set for release by yearend, RBC Capital Markets said in a Thursday note.KT-621's mechanism and phase 1b data have already indicated its potential against marketed biologics dupilumab and lebrikizumab, the brokerage said. Management appears to favor biologics similar to that of dupilumab, given the proposed oral alternative that could expand the market, RBC noted.RBC said KT-621's biologic-like data could unlock a potential upside of over 30% for the company.RBC has a sector perform rating on Kymera Therapeutics, with a higher price target of $116 from $112 previously.Price: 119.57, Change: -3.03, Percent Change: -2.47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0541501648.USD","LU0541502299.USD","BK4115","BK4139","KT","SG9999004220.SGD","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679431622","title":"Kymera Therapeutics price target raised to $150 from $146 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2679431622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679431622?lang=en_us&edition=fundamental","pubTime":"2026-10-30 23:00","pubTimestamp":1793372434,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Kymera Therapeutics (KYMR) to $150 from $146 and keeps an Overweight rating on the shares. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-150-from-146-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-150-from-146-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679412297","title":"Analysts Offer Insights on Healthcare Companies: Resmed (RMD), BridgeBio Pharma (BBIO) and Kymera Therapeutics (KYMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679412297","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679412297?lang=en_us&edition=fundamental","pubTime":"2026-10-30 18:40","pubTimestamp":1793356813,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Resmed (RMD), BridgeBio Pharma (BBIO) and Kymera T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-bridgebio-pharma-bbio-and-kymera-therapeutics-kymr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-bridgebio-pharma-bbio-and-kymera-therapeutics-kymr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B5TLWC47.USD","BK4082","LGHT","LU0109394709.USD","LU2008162690.USD","BK4567","LABU","BK4504","XLV","BK4505","BK4588","KYMR","BK4139","LU0029874061.USD","LU0128526141.USD","BK4581","XBI","BK4585","LU0170899867.USD","RMD","BK4137","HCSG","BBIO","LU2177674079.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679295472","title":"Truist Securities Adjusts Price Target on Kymera Therapeutics to $150 From $136, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2679295472","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679295472?lang=en_us&edition=fundamental","pubTime":"2026-10-30 17:09","pubTimestamp":1793351399,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $141.87, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679298349","title":"Kymera Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2679298349","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679298349?lang=en_us&edition=fundamental","pubTime":"2026-10-30 16:30","pubTimestamp":1793349026,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryKymera Therapeutics, Inc.KYMR.OQreported a quarterly adjusted loss of $1.32 per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nL5N46G0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679062250","title":"Kymera Therapeutics, Inc. : Truist Securities Raises Target Price to $150 from $136","url":"https://stock-news.laohu8.com/highlight/detail?id=2679062250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679062250?lang=en_us&edition=fundamental","pubTime":"2026-10-30 12:02","pubTimestamp":1793332966,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nFWN46G07C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679093289","title":"Kymera Therapeutics price target raised to $144 from $140 at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2679093289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679093289?lang=en_us&edition=fundamental","pubTime":"2026-10-29 22:50","pubTimestamp":1793285424,"startTime":"0","endTime":"0","summary":"Raymond James raised the firm’s price target on Kymera Therapeutics (KYMR) to $144 from $140 and keeps an Outperform rating on the shares. Kymera r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-144-from-140-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-144-from-140-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679881922","title":"Kymera Therapeutics Presents KT-621 Clinical Data for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2679881922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679881922?lang=en_us&edition=fundamental","pubTime":"2026-10-29 21:19","pubTimestamp":1793279989,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Presents KT-621 Clinical Data for Atopic DermatitisKymera Therapeutics completed enrollment in its KT-621 Phase 2b atopic dermatitis trial, with data expected by year-end 2026.Phas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL7LV6xM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403037","title":"Kymera Therapeutics Q3 Net Loss Widens 61% to $132 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679403037?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:14","pubTimestamp":1793272444,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Q3 net loss widens 61% to $132 millionKymera Therapeutics’ third-quarter 2026 net loss widened 61% year over year to $132 million.Collaboration revenue fell to none, while research","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL7sC0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","KYMR","IE00BN0W2T93.GBP","BK4585","IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","IE00BKPKM429.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679405817","title":"Earnings Flash (KYMR) Kymera Therapeutics Posts Q3 Loss $1.32 a Share, vs. FactSet Est of $1.26 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2679405817","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679405817?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:13","pubTimestamp":1793272404,"startTime":"0","endTime":"0","summary":"Earnings Flash (KYMR) Kymera Therapeutics Posts Q3 Loss $1.32 a Share, vs. FactSet Est of $1.26 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403839","title":"Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403839","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679403839?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:05","pubTimestamp":1793271955,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses of $(0.94) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/10/62688609/kymera-therapeutics-q3-eps-1-32-misses-1-27-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679840867","title":"Kymera Therapeutics Q3 EPS USD -1.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2679840867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679840867?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:00","pubTimestamp":1793271606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nPLX6GW5W3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.0751},{"period":"1month","weight":0.2157},{"period":"3month","weight":0.1983},{"period":"6month","weight":0.617},{"period":"1year","weight":1.2305},{"period":"ytd","weight":0.7561}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.0292},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1005},{"period":"ytd","weight":0.0997}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.121889},{"month":6,"riseRate":0.666667,"avgChangeRate":0.163264},{"month":7,"riseRate":0.666667,"avgChangeRate":0.127227},{"month":8,"riseRate":0.666667,"avgChangeRate":0.054225},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.035696},{"month":10,"riseRate":0.714286,"avgChangeRate":0.078618},{"month":11,"riseRate":0.714286,"avgChangeRate":0.166342},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}